520 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA
Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo in the United States, Expanding Its Injectable Portfolio into Skin Quality
Election of Brady Stewart and Vikram Malik as Class II Directors
Reports First Quarter 2026 Financial Results; Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Annual Report to Security Holders
Director Reclassification - Vikram Malik Moves to Class II Director
Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
Financial Results, Press Release
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report